Advances in ocular melanoma and related eye cancers continue to emerge, and new research exploring interferon alpha-2a as a treatment for primary acquired melanosis (PAM) with atypia provides encouraging results for patients and clinicians alike. PAM with atypia is considered a premalignant lesion of the conjunctiva, meaning it can develop into conjunctival melanoma if left untreated. Because of this risk, effective treatments that can control abnormal melanocyte growth while preserving ocular tissue are critical.
In this retrospective case series conducted at a national ocular oncology referral center, researchers evaluated the use of topical interferon alpha-2a (IFN α-2a) for patients diagnosed with PAM with atypia or conjunctival melanoma arising from PAM. Patients received treatment with IFN α-2a, IFN α-2b, or pegylated interferon formulations, and investigators assessed treatment response, side effects, and long-term outcomes.
The study followed 12 patients ranging in age from 38 to 84, with an average follow-up of more than 10 years. Results showed a remarkably high response rate, with 11 out of 12 patients (93%) achieving a complete clinical response after an average treatment period of approximately 5.1 months. This suggests that topical interferon therapy may effectively control or eliminate abnormal melanocytic lesions on the ocular surface.
Equally important was the therapy’s safety profile. Most patients experienced minimal side effects, such as mild eye irritation, dryness, or temporary blurred vision. Only two individuals discontinued treatment due to more severe reactions, and notably, no damage to limbal stem cells was observed, which is an important factor in preserving long-term ocular health.
The study also reported encouraging durability of response. Patients experienced an average progression-free survival of 4.3 years, with only one recurrence observed during follow-up. These outcomes suggest that interferon alpha-2a may serve as a valuable topical therapy for managing premalignant ocular surface lesions and preventing progression to conjunctival melanoma.
While the patient cohort was relatively small, the findings support further investigation through larger prospective clinical trials. As research into ocular melanoma and related melanocytic eye conditions continues, treatments such as interferon alpha-2a may play an important role in preserving vision and preventing more aggressive disease progression.